Reinhold Maurus

Learn More
The authors present the case of a child aged 7 years who suffered from relapsing acute lymphocytic leukemia. Treatment consisting mainly of oral and intrathecal methotrexate and x-ray therapy produced remission of the hematologic symptoms. Three years after the onset of the leukemia, mental deterioration gradually appeared. Radiography of the skull revealed(More)
Late anthracycline cardiotoxicity has been of increasing concern to pediatric oncologists. An increasing number of patients with cardiac dysfunction has been reported without a good correlation between cardiac function or symptoms and routine echocardiographic follow-up. We studied dobutamine stress echocardiography in patients who had received moderate(More)
Lumbar spine bone mineral density and bone mineral metabolism were studied in 13 children three months or more after completion of cytotoxic chemotherapy that included ifosfamide given for different malignancies. Blood and urine were analysed for calcium, phosphorus, and magnesium and blood for alkaline phosphatase activity, parathyroid hormone, and(More)
Cortical calcifications, ween on X-ray in the brain of achild suffering from leukaemia, were submitted to morphological and chemical analysis. The morphology was studied by a combination of low teperature ashing and microscanning. The calcification principally affected axons and capillary walls and consisted of spherules amalgamated into hollow cylinders.(More)
Peptichemio (PTC) was utilized in various advanced and disseminated tumors in children. With the schedule that was used, toxicity was mild. Immediate side effects included anaphylactoid reactions which required close supervision of the patient during infusion of the drug. PTC proved efficacious in advanced neuroblastoma. In patients with bone metastases,(More)
Emesis is one of the most frequent and distressing adverse effects of cytotoxic chemotherapy. Conventional antiemetic regimens are unsatisfactory due to their poor efficacy and their adverse events, particularly in children. Tropisetron (Navoban; Sandoz Pharma Ltd, Basel, Switzerland) belongs to a new class of 5-hydroxytryptamine receptor antagonists with(More)